---
title: "Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285432388.md"
description: "In South San Francisco on May 6, 2026, Lyell Immunopharma, Inc. (Nasdaq: LYEL) shared their financial updates for the first quarter of 2026. The company, specializing in innovative CAR T-cell therapies for cancer patients, announced key business achievements during this period. This late-stage clinical company is making significant strides with its pipeline of next-generation CAR T-cell therapies. The report for the quarter ending on March 31, 2026, underlined the firm's progress and financial standing."
datetime: "2026-05-06T20:07:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285432388.md)
  - [en](https://longbridge.com/en/news/285432388.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285432388.md)
---

# Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

In South San Francisco on May 6, 2026, Lyell Immunopharma, Inc. (Nasdaq: LYEL) shared their financial updates for the first quarter of 2026. The company, specializing in innovative CAR T-cell therapies for cancer patients, announced key business achievements during this period. This late-stage clinical company is making significant strides with its pipeline of next-generation CAR T-cell therapies. The report for the quarter ending on March 31, 2026, underlined the firm's progress and financial standing.

### Related Stocks

- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight](https://longbridge.com/en/news/286895360.md)
- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)
- [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md)
- [06:50 ETBliss Launches Bliss Pro™, an Accessible Pro-Grade Skincare Line of Next-Gen Ingredients and Treatments](https://longbridge.com/en/news/286898081.md)